SeQuent launches Citramox LA injection for cattle, pigs in 10 European countries

Published On 2020-12-11 06:47 GMT   |   Update On 2020-12-11 06:47 GMT

New Delhi: SeQuent Scientific Ltd, a player in animal health space, on Thursday said it has launched Citramox LA suspension injection for cattle and pigs in 10 European countries, including the key markets of western Europe.The injection is of the strength of 150 mg/ml and the product recently received approval through the company''s Spanish subsidiary Laboratorios Karizoo, S.A.,...

Login or Register to read the full article

New Delhi: SeQuent Scientific Ltd, a player in animal health space, on Thursday said it has launched Citramox LA suspension injection for cattle and pigs in 10 European countries, including the key markets of western Europe.

The injection is of the strength of 150 mg/ml and the product recently received approval through the company''s Spanish subsidiary Laboratorios Karizoo, S.A., SeQuent Scientific Ltd said in a regulatory filing.

It will be the first long-acting injectable to be offered by SeQuent in Europe, the company added.

Citramox is the first generic version of Ceva Animal Health Inc''s Vetrimoxin LA, to be approved and launched in Europe, which is an effective antibiotic indicated for the treatment of respiratory infections caused by Mannheimia haemolytica and Pasteurella multocida susceptible to amoxicillin in cattle and pigs, it said.

The market size in Europe for amoxicillin long-acting products is estimated to be around euro 20 million.

Read also: COVID-19: Envoys of 64 countries visit vaccine maker Bharat Biotech, Biological E in Hyderabad

SeQuent said the new approval builds on the recent approvals of Tulazzin (Tulathromycin) and Halofusol (Halofuginone) in Europe, all of which have been received within 12 months of filing reflecting the company''s "growing strengths in introducing new products for the regulated markets."

Read also: Covid-19: UK issues anaphylaxis warning on Pfizer vaccine after adverse reactions



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News